Should I buy Bruker (BRKR) stock or is it too late?

Bruker · Health Care · price $56

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: Guggenheim — 77% of its targets hit on this sector (53 calls tested). It aims for $72 (+28 %), call made on October 2, 2026, maturing on October 2, 2027 (12 d ago).

The 4 reliable analysts $68.50+22 %

The 3 other firms $65+16 %

How to read it: the 4 reliable firms are not filtered by optimism — 3 aim above the price, 1 below, hence their $68.50 median. “The 3 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Bruker

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
Barclays	55 %	+10.5 %	11	$70 +25%
Goldman Sachs	57 %	+10.1 %	7	$35 -38%
Wells Fargo	50 %	+9.3 %	8	$55 -2%
UBS	75 %	+9.2 %	8	$65 +16%
B of A Securities	56 %	+3.9 %	9	$60 +7%
Citigroup	33 %	-10.6 %	9	$53 -6%
SVB Leerink	57 %	+9.9 %	7	—

In short — Should you invest in Bruker? Is it too late, still worth it? Analysts are fairly positive (57% buy, median target $68, i.e. +20%), and the most reliable on BRKR targets even higher. But it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

Median price target $68, i.e. +20% from the current price ($56).
The most reliable firm on BRKR, UBS (75% hit rate, 8 scored calls), targets $65 (call made on September 9, 2026, maturing on September 9, 2027) (+16%) in its most recent call, and $43 (call made on November 4, 2025, maturing on November 4, 2026) (-23%) in the one coming due soonest.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 7 ratings, 3 are neutral.
A 12-month target is not a guaranteed path: the price can fall in the meantime.
Negligible dividend (0.3% yield): your return depends mostly on price appreciation.

The analyst consensus on BRKR

Median target $68 (+20%) · 7 ratings · Buy consensus

Strong Buy00%

Buy457%

Hold343%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Bruker now?

We won't decide for you. The facts: 57% of analysts rate it a buy, median target $68 (+20%), and UBS (most reliable on BRKR, 75%) targets $65. Weigh that against valuation. This is not personalized advice.

Is it too late to invest in Bruker?

Not according to analysts: the median target ($68) is still +20% above the current price ($56) (most reliable on BRKR: UBS, 75%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Bruker still worth investing in?

It depends on the gap between the price ($56) and its estimated value: analysts target $68 on median (+20%), with 57% buys (most reliable on BRKR: UBS, 75%). Cross-check with their real reliability on BRKR and the cautions above. Information, not advice.

What's the main risk in buying BRKR?

The consensus is not unanimous: of 7 ratings, 3 are neutral.

→ Go deeper: the full Bruker profile (consensus, analyst reliability, price target, performance).